Failed trial

Alzheimer; News from the web:

The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”

The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.

Read all about it HERE

Latest research findings on Alzheimer’s

Alzheimer; News from the web:

Next avenue has a great article about the latest theories concerning what causes Alzheimer’s. We link to it below. So far, the results have been beyond disappointing. A class of drugs called “acetylcholinesterase inhibitors” offer marginal functional improvements, but that’s been it. Things are starting to change, though.

Read all about it HERE